Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
View Patent ↗A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the fluid to light of an appropriate wavelength to damage the nucleic acid of the pathogen and to substantially maintain the damage to the pathogenic nucleic acids to allow for subsequent transfusion into a recipient.
1. A process for inactivating or inhibiting the proliferation of mononuclear cells in response to a stimulus comprising the steps of:
adding to the mononuclear cells 500 μM riboflavin and irradiating said mononuclear cells with 6.2 J UV light/mL for approximately 8-10 minutes to make treated mononuclear cells;
exposing the treated mononuclear cells to a stimulus; and thereby
inactivating or inhibiting the proliferation of the treated mononuclear cells in response to the stimulus.
2. The process of claim 1 wherein the exposing step further includes the step of exposing the treated mononuclear cells to mitogens, allogeneic stimulator cells and antibodies.
3. The process of claim 1 whereby the treated mononuclear cells are human.
4. A process for inhibiting the antigen presentation capabilities of mononuclear cells comprising the step of:
adding to the mononuclear cells 500 μM riboflavin and irradiating with 6.2 J UV light/mL for approximately 8-10 minutes to make treated mononuclear cells;
wherein the antigen presentation capabilities of the treated mononuclear cells are inhibited.
5. A process for inactivating or inhibiting cytokine production by mononuclear cells in response to a stimulus comprising the steps of:
adding to the mononuclear cells 500 μM riboflavin and irradiating said mononuclear cells with 6.2 J UV light/mL for approximately 8-10 minutes to make treated mononuclear cells;
exposing the treated mononuclear cells to a stimulus; and thereby
inactivating or inhibiting the production of cytokines in response to the stimulus.
6. The process of claim 5 wherein the exposing step further includes the step of exposing the treated mononuclear cells to mitogens, allogeneic stimulator cells and antibodies.
7. The process of claim 5 whereby the treated mononuclear cells are human.